Last updated: April 23, 2026
What is mesalamine’s supplier landscape?
Mesalamine (also known as 5-aminosalicylic acid, 5-ASA) is supplied across two levels:
- Active pharmaceutical ingredient (API): 5-ASA manufactured for use in delayed-release and extended-release oral products.
- Finished-dose and product supply: branded and generic mesalamine delayed-release tablets, extended-release capsules, and rectal formulations sourced from multiple global manufacturers.
Because mesalamine is a widely used generic API, supplier lists vary by dosage form, release technology (delayed-release vs extended-release), and submission history (ANDA/DMF ownership and site approvals). The current market is dominated by established generic API manufacturers plus contract manufacturers that package and release finished dosage forms for multiple labelers.
Which API suppliers and manufacturers support mesalamine?
The dominant API supply pattern for mesalamine is:
- API producers that hold DMFs (commonly via ASMF/DMF pathways).
- Integrated chemical manufacturers that supply 5-ASA to multiple formulation OEMs.
For business planning, the practical “supplier set” is defined by:
- API supply into ANDA holders for oral delayed/extended release and
- API supply into finished-dose manufacturers for rectal formulations.
Which finished-dose suppliers matter commercially?
Mesalamine finished products are made and supplied by a mix of:
- Original manufacturers (brand owners historically)
- Generic/contract manufacturers producing tablets, capsules, and enemas/suppositories
- Labelers who own the ANDA/label but do not always manufacture
The supplier choices that affect timelines and risk are typically constrained by:
- whether the manufacturer supports the specific release mechanism (pH-dependent vs time-dependent vs coating systems),
- capacity for the specific market strength (common strengths include 1.2 g and 4 g for oral formulations; rectal strengths depend on product type),
- and regulatory history for the specific dosage form.
How do mesalamine dosage forms change the supplier list?
Mesalamine is sold in multiple regulatory dosage forms, each with different manufacturing and packaging requirements:
- Oral delayed-release tablets (typical for colitis therapies)
- Oral extended-release capsules (designed for sustained delivery)
- Rectal formulations (enemas and suppositories; often tighter controls for viscosity, droplet/particle distribution, and stability)
- Higher-dose oral regimens (dose strength drives equipment, film/coating and granulation operations)
Supplier eligibility usually tracks these categories more than it tracks the raw API itself.
What supplier inputs should procurement screen for?
Procurement screening for mesalamine should focus on:
- DMF/ASMF ownership or listed supplier status for the API used by the ANDA
- GMP status and inspected manufacturing sites
- Particle size and quality specs tied to performance for delayed/extended-release products
- Stability and shelf-life documentation for the finished dosage form
- Packaging configuration (bottle vs blister; carton count; tamper evidence for US market)
Key takeaways
- Mesalamine’s supplier universe is split between 5-ASA API producers and finished-dose manufacturers that deliver specific delayed-release/extended-release/rectal dosage forms.
- For sourcing decisions, the effective supplier set is defined by ANDA/DMF-linked eligibility and dosage-form release technology, not by API supply alone.
- Supplier screening should prioritize GMP site history, regulatory linkage (DMF/ASMF), and product-spec controls that tie to release performance.
FAQs
-
Is the mesalamine API supplier the same as the finished-dose supplier?
No. Many labelers source API from one set of DMF holders and contract manufacturing of finished dosage forms to different OEMs.
-
What most affects mesalamine supplier qualification?
Match to the correct dosage form (delayed vs extended vs rectal) and the regulatory linkage to the product’s DMF/ANDA history.
-
Do mesalamine formulations require different manufacturing technology by supplier?
Yes. Release mechanisms require specific coating/granulation systems, equipment, and validated controls.
-
Why does mesalamine have many suppliers?
It is a mature active with broad generic competition and widespread chemical manufacturing capacity for 5-ASA.
-
What is the most important procurement document set for mesalamine?
API and finished-dose documentation tied to GMP compliance, specifications, stability, and regulatory submissions (DMF/ANDA/ASMF-linked materials).
References
[1] U.S. FDA. Drug Master File (DMF) database and guidance documents for API submissions. FDA.
[2] U.S. FDA. ANDA database and Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA.
[3] U.S. FDA. Current Good Manufacturing Practice (CGMP) regulations for APIs and drug products. FDA.
